Journal
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
Volume 4, Issue 4, Pages 409-416Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/EGH.10.48
Keywords
Clostridium difficile infection; colitis; community acquired; nosocomial
Categories
Funding
- ViroPharma
- Sanofi Pasteur
- Massachusetts Biologic Laboratories
- Optimer Pharmaceuticals
- Salix Pharmaceuticals
- Genzyme Corporation
Ask authors/readers for more resources
Clostridium difficile infection (CDI) is a leading cause of nosocomial infections, with disease severity ranging from mild diarrhea to fulminant colitis. The incidence and severity of CDI has been on the rise over the last 10-20 years, with CDI being increasingly described outside healthcare settings and in populations previously thought to be at low risk. There has also been an increase in the morbidity, mortality and economic burden associated with CDI in the last several years. This increasing incidence and severity is thought to be at least partially due to frequent antibiotic use and the emergence of a hypervirulent C. difficile strain.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available